BBH - (VanEck Vectors Biotech ETF)

 BBHのチャート


 BBHの企業情報

symbol -
会社名
分野(sector)   
産業(industry)   
業種   
概要     
本社所在地 --
代表者氏名
代表者役職名
電話番号 --
設立年月日 --
市場名 --
ipoyear ―年
従業員数 --
url --
nasdaq_url https://www.nasdaq.com/symbol/bbh
adr_tso
EBITDA
終値(lastsale) 129.41
時価総額(marketcap) 478364453.23
時価総額
売上高
企業価値(EV)
当期純利益
決算概要

 BBHのテクニカル分析


 BBHのニュース

   Biogen Could Send Biotech ETFs on a Wild Ride  2021/06/07 13:00:30 ETF Trends
Biotechnology sector-related exchange traded funds are in for a wild ride as Biogen (NasdaqGS: BIIB) is set to receive a verdict from the Food and Drug Administration on its Alzheimers drug. Biogen shares are already up 5.8% on Friday ahead of the FDAs decision. Meanwhile, the VanEck Vectors Biotech ETF (BBH) rose 1.8% and the iShares [] The post Biogen Could Send Biotech ETFs on a Wild Ride appeared first on ETF Trends .
   Launch of BBH Select Series - Mid Cap Fund  2021/05/25 13:00:00 PR Newswire
NEW YORK, May 25, 2021 /PRNewswire/ -- Brown Brothers Harriman & Co. (BBH) announces the launch of the BBH Select Series - Mid Cap Fund (ticker: BBMIX), the newest addition to BBH''s Select Series line up. The fund will be managed by Timothy Harris, Senior Vice President. The BBH Select
   Illumina Earnings, Forward Guidance Strengthen Biotech ETFs  2021/02/12 20:03:08 ETF Trends
Biotechnology sector-related exchange traded funds strengthened after Illumina (NasdaqGS: ILMN) announced better-than-expected quarterly earnings and an optimistic 2021 outlook. On Friday, the VanEck Vectors Biotech ETF (BBH) rose 2.0% and iShares Nasdaq Biotechnology ETF (IBB) gained 0.5%. Meanwhile, Illumina shares jumped 13.4%. ILMN makes up 5.9% of BBH and 4.7% of IBB. Illumina revealed a […] The post Illumina Earnings, Forward Guidance Strengthen Biotech ETFs appeared first on ETF Trends .
   IPOs Are Back. Get In On the Action with the BBH ETF  2021/02/09 14:26:11 ETF Trends
2020 saw a lot of initial public offerings (IPOs) put on hold thanks to Covid-19. Now that a global vaccine rollout is underway, biotech IPOs are hitting the markets and boosting the VanEck Vectors® Biotech ETF (BBH). “Biotechnology companies continue their race to the public equity markets. Seven companies, all in the biotech or health-care space, […] The post IPOs Are Back. Get In On the Action with the BBH ETF appeared first on ETF Trends .
   Biotechnology ETFs Soar on Biogen’s New Alzheimer’s Drug  2021/01/29 23:27:07 ETF Trends
Biotechnology stocks and sector-related exchange traded funds stood out Friday after regulators breathed new life into Biogen (NasdaqGS: BIIB) and its partner Eisai Co. (ESALY) on a new Alzheimer’s drug candidate. Among the top performing non-leveraged ETFs of Friday, the VanEck Vectors Biotech ETF (BBH) rose 2.1% and iShares Nasdaq Biotechnology ETF (IBB) gained 0.6%. […] The post Biotechnology ETFs Soar on Biogen’s New Alzheimer’s Drug appeared first on ETF Trends .
   ETFs to benefit from fee wars BBH survey finds  2020/12/09 12:14:33 ETF Express
ETFs to benefit from fee wars BBH survey finds Submitted By Beverly Chandler | 09/12/2020 - 12:14pm Brown Brothers Harriman has launched its first C-Suite Asset Manager Survey, which found that Covid-19, the economy and fee wars are the top concerns for C-suite executives. The firm writes that as a result of those pressures, 52 per cent of asset managers plan to reduce the expense ratios on their products in the next year. Some 35 per cent of respondents said they are evaluating new strategies such as ETFs to expand their product suite. The survey found that ETFs remain a core component of the product suite, with 63 per cent of respondents either having ETFs or are looking to enter the market. ETFs present an opportunity for asset managers and active managers to meet investor demand, the survey says. The ETF market has had steady gains in 2020, with many large asset managers already having a strong representation in the ETF market. Some 89 per cent of large asset managers currently have ETFs or are looking to enter the market, according to the survey.
   A Divergence Has Occurred In Healthcare  2020/08/31 13:29:27 Benzinga
For the first four months of the market’s cornavirus recovery, one of the key themes was the dominance of biotech. In the 15 weeks from the market’s lows on March 23 until July 17, the VanEck Vectors Biotech ETF (NYSE: BBH ) rallied nearly 60% and took in inflows of nearly $84 million. The fund flew past its previous all-time high of $141 to a new all-time high of $172 thanks to massive rallies in stocks like Amgen Inc (NASDAQ: AMGN ), Moderna Inc (NASDAQ: MRNA ), and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ), all of which have made new all-time highs this summer. Much of this optimism has been driven by the development of vaccine and treatment candidates for COVID-19. Moderna has a $1.5 billion deal to supply the U.S. government with 100 million doses of its vaccine … Full story available on Benzinga.com
   Illumina Earnings, Forward Guidance Strengthen Biotech ETFs  2021/02/12 20:03:08 ETF Trends
Biotechnology sector-related exchange traded funds strengthened after Illumina (NasdaqGS: ILMN) announced better-than-expected quarterly earnings and an optimistic 2021 outlook. On Friday, the VanEck Vectors Biotech ETF (BBH) rose 2.0% and iShares Nasdaq Biotechnology ETF (IBB) gained 0.5%. Meanwhile, Illumina shares jumped 13.4%. ILMN makes up 5.9% of BBH and 4.7% of IBB. Illumina revealed a […] The post Illumina Earnings, Forward Guidance Strengthen Biotech ETFs appeared first on ETF Trends .
   IPOs Are Back. Get In On the Action with the BBH ETF  2021/02/09 14:26:11 ETF Trends
2020 saw a lot of initial public offerings (IPOs) put on hold thanks to Covid-19. Now that a global vaccine rollout is underway, biotech IPOs are hitting the markets and boosting the VanEck Vectors® Biotech ETF (BBH). “Biotechnology companies continue their race to the public equity markets. Seven companies, all in the biotech or health-care space, […] The post IPOs Are Back. Get In On the Action with the BBH ETF appeared first on ETF Trends .
   Biotechnology ETFs Soar on Biogen’s New Alzheimer’s Drug  2021/01/29 23:27:07 ETF Trends
Biotechnology stocks and sector-related exchange traded funds stood out Friday after regulators breathed new life into Biogen (NasdaqGS: BIIB) and its partner Eisai Co. (ESALY) on a new Alzheimer’s drug candidate. Among the top performing non-leveraged ETFs of Friday, the VanEck Vectors Biotech ETF (BBH) rose 2.1% and iShares Nasdaq Biotechnology ETF (IBB) gained 0.6%. […] The post Biotechnology ETFs Soar on Biogen’s New Alzheimer’s Drug appeared first on ETF Trends .
   ETFs to benefit from fee wars BBH survey finds  2020/12/09 12:14:33 ETF Express
ETFs to benefit from fee wars BBH survey finds Submitted By Beverly Chandler | 09/12/2020 - 12:14pm Brown Brothers Harriman has launched its first C-Suite Asset Manager Survey, which found that Covid-19, the economy and fee wars are the top concerns for C-suite executives. The firm writes that as a result of those pressures, 52 per cent of asset managers plan to reduce the expense ratios on their products in the next year. Some 35 per cent of respondents said they are evaluating new strategies such as ETFs to expand their product suite. The survey found that ETFs remain a core component of the product suite, with 63 per cent of respondents either having ETFs or are looking to enter the market. ETFs present an opportunity for asset managers and active managers to meet investor demand, the survey says. The ETF market has had steady gains in 2020, with many large asset managers already having a strong representation in the ETF market. Some 89 per cent of large asset managers currently have ETFs or are looking to enter the market, according to the survey.
   A Divergence Has Occurred In Healthcare  2020/08/31 13:29:27 Benzinga
For the first four months of the market’s cornavirus recovery, one of the key themes was the dominance of biotech. In the 15 weeks from the market’s lows on March 23 until July 17, the VanEck Vectors Biotech ETF (NYSE: BBH ) rallied nearly 60% and took in inflows of nearly $84 million. The fund flew past its previous all-time high of $141 to a new all-time high of $172 thanks to massive rallies in stocks like Amgen Inc (NASDAQ: AMGN ), Moderna Inc (NASDAQ: MRNA ), and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ), all of which have made new all-time highs this summer. Much of this optimism has been driven by the development of vaccine and treatment candidates for COVID-19. Moderna has a $1.5 billion deal to supply the U.S. government with 100 million doses of its vaccine … Full story available on Benzinga.com

 twitter  (公式ツイッターやCEOツイッターなど)